TNXP – Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals Holding C

TNXP

$4.01

Name : Tonix Pharmaceuticals Holding C

Sector : Healthcare

Industry: Biotechnology

Mark. Cap: $77,823,224.00

EPSttm : -12.39

Tonix Pharmaceuticals Holding C

$4.01

2.32%

$0.095

TNXP — Price & Float Short

—— Fair value ★ EPS beat ★ EPS miss —— Target Price

Float Short %

17.21

Margin Of Safety %

Put/Call OI Ratio

0.19

EPS Next Q Diff

EPS Last/This Y

4.79

EPS This/Next Y

2.96

Price

4.12

Target Price

31.6

Analyst Recom

Performance Q

-65.75

Upside

-10,548.8%

Beta

1.9

Ticker: TNXP

22 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-10-12	TNXP	6.63	0.17	1.55	2045
2026-10-13	TNXP	6.13	0.31	0.54	2432
2026-10-14	TNXP	6.38	0.30	0.65	2438
2026-10-15	TNXP	6.44	0.30	0.89	2450
2026-10-16	TNXP	6.07	0.26	0.05	2398
2026-10-19	TNXP	5.71	0.38	0.06	1724
2026-10-20	TNXP	5.77	0.31	0.12	1950
2026-10-21	TNXP	5.44	0.30	0.00	2080
2026-10-22	TNXP	5.13	0.29	0.05	2113
2026-10-23	TNXP	5.17	0.28	0.06	2202
2026-10-26	TNXP	5.29	0.27	0.11	2257
2026-10-27	TNXP	5.38	0.26	0.00	2435
2026-10-28	TNXP	5.45	0.26	0.15	2446
2026-10-29	TNXP	5.27	0.25	0.67	2478
2026-10-30	TNXP	5.1	0.25	0.00	2488
2026-11-02	TNXP	5.14	0.25	0.00	2510
2026-11-03	TNXP	5.2	0.24	0.00	2500
2026-11-04	TNXP	5.11	0.24	0.00	2501
2026-11-05	TNXP	4.59	0.24	0.02	2502
2026-11-06	TNXP	4.73	0.24	0.02	2570
2026-11-09	TNXP	4.49	0.23	0.48	2630
2026-11-10	TNXP	4.11	0.19	0.00	2601
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

22 items 1 of 1

22 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-10-12	TNXP	6.64	37.0	-	-9.95
2026-10-13	TNXP	6.12	37.0	-	-9.95
2026-10-14	TNXP	6.38	37.0	-	-9.95
2026-10-15	TNXP	6.42	37.0	-	-9.95
2026-10-16	TNXP	6.06	37.0	-	-9.95
2026-10-19	TNXP	5.72	37.0	-	-9.95
2026-10-20	TNXP	5.72	37.0	-	-9.95
2026-10-21	TNXP	5.76	37.0	-	-9.95
2026-10-22	TNXP	5.13	37.0	-	-9.95
2026-10-23	TNXP	5.16	37.0	-	-9.95
2026-10-26	TNXP	5.30	38.5	-	-9.82
2026-10-27	TNXP	5.38	38.5	-	-9.82
2026-10-28	TNXP	5.36	38.5	-	-9.82
2026-10-29	TNXP	5.28	38.5	-	-9.82
2026-10-30	TNXP	5.09	39.4	-	-9.78
2026-11-02	TNXP	5.13	39.4	-	-9.78
2026-11-03	TNXP	5.21	39.4	-	-9.78
2026-11-04	TNXP	5.10	39.4	-	-9.78
2026-11-05	TNXP	4.59	39.4	-	-9.78
2026-11-06	TNXP	4.74	39.4	-	-9.78
2026-11-09	TNXP	4.51	39.4	-	-9.78
2026-11-10	TNXP	4.12	39.4	-	-9.78
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

22 items 1 of 1

21 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-10-12	TNXP	30.46	10.12	17.19
2026-10-13	TNXP	30.46	10.12	17.19
2026-10-14	TNXP	30.46	10.12	17.19
2026-10-15	TNXP	30.46	10.12	17.19
2026-10-16	TNXP	30.46	10.12	17.19
2026-10-19	TNXP	30.46	9.86	17.19
2026-10-20	TNXP	30.46	9.86	17.19
2026-10-21	TNXP	30.46	9.86	17.19
2026-10-22	TNXP	30.46	9.86	17.19
2026-10-23	TNXP	30.46	9.86	17.19
2026-10-26	TNXP	30.46	9.44	17.19
2026-10-27	TNXP	30.46	9.44	17.21
2026-10-28	TNXP	30.46	9.44	17.21
2026-10-29	TNXP	30.46	9.44	17.21
2026-10-30	TNXP	30.46	9.44	17.21
2026-11-02	TNXP	30.46	9.34	17.21
2026-11-03	TNXP	30.46	9.34	17.21
2026-11-05	TNXP	30.46	9.34	17.21
2026-11-06	TNXP	30.46	9.34	17.21
2026-11-09	TNXP	30.46	8.31	17.21
2026-11-10	TNXP	30.46	8.31	17.21
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

21 items 1 of 1

Last Quarter Act. EPS

Avg. EPS Est. Current Quarter

-2.24

Avg. EPS Est. Next Quarter

-2.3

Insider Transactions

30.46

Institutional Transactions

8.31

Beta

1.9

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

100

Max Drawdown 5-Year %

-100

Target Price

31.6

P/E

Forward P/E

PEG

P/S

1.63

P/B

0.39

P/Free Cash Flow

EPS

-12.24

Average EPS Est. Cur. Y

-9.78

EPS Next Y. (Est.)

-6.82

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-420.45

Relative Volume

1.44

Return on Equity vs Sector %

-100

Return on Equity vs Industry %

-97.3

EPS 1 7Days Diff

0.2

EPS 1 30Days Diff

0.17

EBIT Estimation

◆ TNXP Healthcare

$4.10

📉

Swing / Pullback

Buy the dip on strong trends

N/A

WEAK

Trend

20/20

Pullback

13/25

Volume

3/15

Valuation

12/20

TP/AR

2/10

Options

5/10

RSI

16.1

Range 1M

3.2%

Sup Dist

2.7%

🚀

Momentum Growth

Ride accelerating trends

N/A

WEAK

Momentum

7/25

Growth

23/30

Estimates

0/20

Inst/Vol

7/15

Options

5/10

EPS Yr

27.1%

EPS NY

41.8%

52W%

0.6%

💎

Long-Term Value

Quality companies, undervalued

N/A

WEAK

🟢 BUY +670.7% upside

Quality

6/30

Valuation

16/30

Growth

17/25

Stability

7/10

LT Trend

4/5

Upside

+670.7%

Quality

TNXP — P/E HistoricalBiotechnology

Tonix Pharmaceuticals Holding C

Sector: Healthcare

Industry: Biotechnology

Employees: 142

Tonix Pharmaceuticals Holding Corp., a fully integrated biopharmaceutical company, develops and commercializes therapies for central nervous system (CNS) disorders, immunology and immuno-oncology, infectious diseases, and rare diseases in the United States. The company offers TONMYA, a cyclobenzaprine HCl sublingual tablet for the treatment of fibromyalgia. It also markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults. In addition, the company develops TNX-102 SL, a cyclobenzaprine HCl sublingual tablet for the treatment of major depressive disorder and acute stress reaction/acute stress disorder; TNX-1300, a double-mutant cocaine esterase for the treatment of cocaine intoxication; TNX-1500, an Fc-modified humanized monoclonal antibody to prevent kidney transplant rejection, as well as to treat autoimmune conditions; TNX-4800, a humanized monoclonal antibody for the seasonal prevention of Lyme disease; and TNX-2900, an intranasal oxytocin potentiated with magnesium for the treatment of Prader-Willi syndrome. Further, it is developing TNX-1900, an intranasal potentiated oxytocin for the treatment of binge eating disorder, adolescent obesity, and bone health in pediatric autism, and arginine-vasopressin deficiency; TNX-801, a live horsepox vaccine for the prevention of smallpox and mpox; TNX-4200, a small molecule broad-spectrum antiviral agent targeting CD45 for the treatment or prevention of viral disease; TNX-4900, a highly selective small-molecule Sigma-1 receptor antagonist for neuropathic pain; TNX-1700, a recombinant Trefoil Factor Family 2 fusion protein for the treatment of gastric and colorectal cancers; and TNX-1800 and TNX-1850, live modified horsepox vaccines for the prevention of COVID. Tonix Pharmaceuticals Holding Corp. was founded in 2007 and is based in Berkeley Heights, New Jersey.

TNXP

Latest News

—

Caricamento notizie per TNXP…

stock quote shares TNXP – Tonix Pharmaceuticals Holding Corp. Stock Price stock today

news today TNXP – Tonix Pharmaceuticals Holding Corp. stock forecast ,stock prediction 2023 2024 2025

marketwatch TNXP – Tonix Pharmaceuticals Holding Corp. yahoo finance google finance

stock history TNXP – Tonix Pharmaceuticals Holding Corp. invest stock market

stock prices TNXP premarket after hours

ticker TNXP fair value insiders trading

TNXP – Tonix Pharmaceuticals Holding Corp.

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Upside

Beta

Ticker: TNXP

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Latest News

Last Quarter Act. EPS

Average EPS Est. Cur. Y